Fluidigm Corporation today announced it ranked 185 on Deloitte's
Technology Fast 500™ list, which ranks the 500 fastest growing
technology, media, telecommunications, life sciences, and clean
technology companies in North America from 2007 to 2011. Fluidigm grew
489% during this period. Fluidigm was the fastest growing Life Sciences
company in the San Francisco Bay Area, according to the Fast 500™
rankings. The Life Sciences category includes
Biotechnology/Pharmaceutical, Medical Devices, and Scientific/Technical
Fluidigm President and Chief Executive Officer Gajus Worthington
attributes the company's ranking and growth to life science researchers'
enthusiasm for Fluidigm's industry-leading genetic analysis tools, which
are used to explore the causes and characteristics of diseases at the
level of a single cell.
"Researchers increasingly understand that analyzing genetics at the
single-cell level is crucial. In order to make sense of challenges and
opportunities in healthcare ranging from cancer treatment to stem cell
therapy, essential information can only be uncovered by looking at the
DNA and RNA of every individual cell in a sample, rather than averaging
the data of all the cells in the sample," said Worthington. "As the
field recognizes the importance of single-cell research, they are
turning to Fluidigm's market-leading products because we provide fully
automated, cost-effective tools to conduct this research. We believe
there are essentially an unlimited number of cells that need this level
of scrutiny, so we are confident single-cell genomics will continue to
drive Fluidigm's growth for the foreseeable future."
Worthington added that Fluidigm is both delighted and honored to be
recognized for its strong growth by being named to the Deloitte 2012
Technology Fast 500 list for the second year in a row. "It is a
wonderful honor and we are thankful for this recognition of our
performance to date," said Worthington.
"The companies on the Fast 500 list are among thos that have
demonstrated remarkable innovation, creativity and business savvy," said
Bill Ribaudo partner, Deloitte & Touche LLP and national TMT leader for
audit and enterprise risk services (AERS). "As a result, these companies
have continued to successfully forge ahead in a challenging economic
environment. We applaud the leadership and employees of Fluidigm for
this impressive accomplishment."
"We are proud to honor the 2012 Technology Fast 500™ companies, and
commend them for their outstanding growth," said Eric Openshaw, vice
chairman, Deloitte LLP and U.S. technology, media and telecommunications
(TMT) leader. "These ground-breaking companies have outpaced their
competition and are reinventing the way we do business today."
About Deloitte's 2012 Technology Fast 500™
Technology Fast 500, conducted by Deloitte & Touche LLP, provides a
ranking of the fastest growing technology, media, telecommunications,
life sciences and clean technology companies - both public and private -
in North America. Technology Fast 500 award winners are selected based
on percentage fiscal year revenue growth from 2007 to 2011.
In order to be eligible for Technology Fast 500 recognition, companies
must own proprietary intellectual property or technology that is sold to
customers in products that contribute to a majority of the company's
operating revenues. Companies must have base-year operating revenues of
at least $50,000 USD or CD, and current-year operating revenues of at
least $5 million USD or CD. Additionally, companies must be in business
for a minimum of five years, and be headquartered within North America.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements relating to market trends, our
products and our future growth. Forward-looking statements are subject
to numerous risks and uncertainties that could cause actual results to
differ materially from currently anticipated results, including but not
limited to, risks relating to market acceptance of our products,
competition, our sales, marketing and research and development
activities, changes in spending or budget priorities by customers, and
risk associated with international operations. Information on these and
additional risks, uncertainties, and other information affecting
Fluidigm's business and operating results are contained in our filings
with the Securities and Exchange Commission, including our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2012. These
forward-looking statements speak only as of the date hereof. Fluidigm
Corporation disclaims any obligation to update these forward-looking
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic
systems for growth markets in the life science and agricultural
biotechnology, or Ag-Bio, industries. Fluidigm's proprietary
microfluidic systems consist of instruments and consumables, including
integrated fluidic circuits (IFCs), assays and other reagents. These
systems are designed to significantly simplify experimental workflow,
increase throughput and reduce costs, while providing the excellent data
quality demanded by customers. Fluidigm actively markets four
microfluidic systems, including 13 different IFCs, to leading academic
institutions, diagnostic laboratories, and pharmaceutical, biotechnology
and Ag-Bio companies. Fluidigm products are marketed for research
purposes only (not for diagnostic use).
For more information, please visit www.fluidigm.com.
Fluidigm, the Fluidigm logo and C1 are trademarks or
registered trademarks of Fluidigm Corporation.
[ Back To NFVZone's Homepage ]